Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 1 klinisk studie for å evaluere sikkerhet, effekt og farmakokinetikk av IPS101A hos pasienter med Parkinsons sykdom

3. november 2026 oppdatert av: Innopeutics Corporation

Doseøkning, enkelt-senter, åpen merking Fase 1 klinisk studie for å evaluere sikkerhet, effekt og farmakokinetikk til Adeno-assosiert virus(AAV) genterapiprodukt IPS101A hos Parkinson-pasienter med Hoehn-Yahr stadium 4-5, diagnostisert i mer enn 10 år og ukontrollert av all tilgjengelig monoterapi eller kombinasjonsterapi

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

6

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Seoul, Sør -Korea
        • Rekruttering
        • Severance Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
  2. Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
  3. Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
  4. Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
  5. Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.

Exclusion Criteria:

  1. Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
  2. Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
  3. Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
  4. Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
  5. Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
  6. Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Low dose (1.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

Eksperimentell: High dose(2.0 x 10^10 vg/patient)

IPS101A

The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety Evaluation: dose-limiting toxicity (DLT)
Tidsramme: Baseline to Week 8

Frequency and proportion of subjects who developed dose-limiting toxicity (DLT)

Baseline to Week 8
Safety Evaluation: Severity and frequency of reported adverse events
Tidsramme: Baseline to Week 52

Assess severity and frequency of reported adverse events

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
Tidsramme: Baseline to Week 52

The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.

Baseline to Week 52
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
Tidsramme: Baseline to Week 52

The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur.

Baseline to Week 52

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
Tidsramme: Baseline to Weeks 4, 12, 24, 36, and 52.

Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease.

Baseline to Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Hoehn & Yahr stage (defined on/off)
Tidsramme: Weeks 1, 4, 12, 24, 36, and 52.

This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease.

Weeks 1, 4, 12, 24, 36, and 52.
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
Tidsramme: Weeks 4, 12, 24, 36, and 52.

This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease.

Weeks 4, 12, 24, 36, and 52.
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
Tidsramme: Weeks 4, 12, 24, 36, and 52

The scale consists of 800 points, and a higher score indicates a lower quality of life.

Weeks 4, 12, 24, 36, and 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
Tidsramme: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
Tidsramme: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
Tidsramme: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using ELISA

Baseline to Week 52
Assessment of AAV9 shedding in biological specimens-urine
Tidsramme: Baseline to Week 52

After IP administration, the detection of AAV genome was measured using q-PCR.

Baseline to Week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. mai 2026

Primær fullføring (Antatt)

30. juni 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

17. november 2025

Først innsendt som oppfylte QC-kriteriene

19. januar 2026

Først lagt ut (Faktiske)

27. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere